Biogennix Names Chief Financial Officer

Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft substitutes used for bone fusion procedures has named Robert Bazier its new chief financial officer. News of Baizer’s arrival comes on the heels of Biogennix reporting its 11,000th patient benchmark. 
 
Baizer has over 25 years of professional finance experience, with the past 10 years focused specifically in the biotechnology sector. Most recently, he led a private equity group that partnered with Qualcomm Inc. to develop a suite of wireless medical devices. Prior to that, he formed and led an investment company that provided financing to emerging biotech companies during the financial crisis, which resulted in two portfolio companies becoming publicly traded. He started his finance career with TD Securities (USA) LLC, the investment bank and broker-dealer affiliate of Toronto-Dominion, where he worked from 1993 through 2008. Most recently, Baizer was the managing director responsible for TD’s U.S. derivatives business.  
 
Baizer has an M.B.A. from Cornell University’s Johnson Graduate School of Management and a bachelor of science degree in electrical engineering from the University of California San Diego.
 
“We are pleased to have Robert as a new key member of our Biogennix leadership team. Robert is a great fit and brings strong business, medical device and financial leadership experience to our team, further positioning us for continued growth,” said Michael Roux, Biogennix’s general manager. 
 
In steady growth mode, Biogennix also has announced benchmark news that its products have now been used in more than 11,000 patients, a number that has increased by more than 5,000 patients since Q4 of 2017.  
 
The company’s bone graft substitutes, osteoSPAN and Morpheus are resorbable, osteoconductive scaffolds ideally suited for bone regeneration and optimal handling by surgeons. Biogennix’s composites of calcium phosphate and calcium carbonate have complete interconnected porosity and the optimal pore diameter for bone reconstruction. Available in strips, granules and moldable putty, the products are indicated for orthopedic applications including the posterolateral spine, long bone and pelvis. 
 
“We’re proud that our osteoSPAN and Morpheus bone graft products have been so well received by the clinician and patient communities and that we’ve been able to contribute to such positive post-op outcomes for more than 11,000 spine surgery patients,” said Clay Shors, Biogennix’s president. “We firmly believe that our products are fast becoming the new standard of effectiveness and ease of use when it comes to bone graft substitutes.” 
 
The osteoSPAN bone graft substitute is available in either granular form (1-4mm) or in blocks, called “Fusion Kits.” The granules and blocks serve as bone graft substitutes and are mixable with autograft for use as a bone graft extender in the posterolateral spine.  Handling characteristics favored by surgeons include the product’s compressive strength, hydrophilicity, and easy integration with autogenous bone. 
 
Morpheus is a moldable variation of the original osteoSPAN product. The 1-2mm osteoSPAN granules are combined with an organic binder which provides improved intraoperative handling and facilitates placement and containment of the implant. The binder dissolves quickly and does not interfere with the osteoconductive properties of the granules. The granules are gradually resorbed and remodeled by bone over the next six to 12 months.
 
Biogennix designs, manufactures and distributes all of its products from its Irvine-based facilities.   
 
Biogennix is a fully-integrated osteobiologic company headquartered in Irvine, Calif., that develops, manufactures, and distributes proprietary bone graft substitutes used in bone fusion procedures.